Search
Trevi Therapeutics Inc
TRVIAdd to Watchlist
17.700USD
+0.490+2.85%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
2.27BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
11
analysts
Buy
Current Rating
24.700
Target Price
+43.52%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Trevi Therapeutics Inc
TRVI
11
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Trevi Therapeutics Inc's price target?
Analysts forecast that Trevi Therapeutics Inc's price target is USD 20.00, with the highest forecast at USD 27.00 and the lowest forecast at USD 11.00.
How have Trevi Therapeutics IncTRVI's recent earnings per share performed?
The market expectation was USD -0.09, while Trevi Therapeutics IncTRVI's earnings per share (EPS) for the previous quarter was USD -0.06. EPS for the next quarter is expected at USD -0.11.
What is the analyst rating for Trevi Therapeutics Inc?
Based on the ratings of Trevi Therapeutics Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
